Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InotivSTU:BS50 5-Year RORE % is -5.40 as of Mar. 2026. The stock has 4 warning signs investors should review. Among 180 Medical Diagnostics & Research companies, Inotiv ranks better than 57.78% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Inotiv's 5-Year RORE % for the quarter that ended in Mar. 2026 was -5.40%.
The industry rank for Inotiv's 5-Year RORE % or its related term are showing as below:
STU:BS50's 5-Year RORE % is ranked better than 57.78% of 180
companies
in the Medical Diagnostics & Research industry
Industry Median: -11.675
vs STU:BS50: -5.40
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Inotiv 5-Year RORE % Related Terms
Inotiv 5-Year RORE % Historical Data
* Premium members only.
The historical data trend for Inotiv's 5-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:BS50 vs NSTM, PRPH, IDTA: 5-Year RORE % Comparison
For the Diagnostics & Research subindustry, Inotiv's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inotiv 5-Year RORE % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Inotiv's 5-Year RORE % distribution charts can be found below:
* The bar in red indicates where Inotiv's 5-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 5-year before.
Inotiv (STU:BS50) has a 5-Year RORE % of -5.40 as of Mar. 2026. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on Inotiv and its competitors. According to the industry distribution chart, Inotiv ranks #76 out of 180 companies in the Medical Diagnostics & Research industry, placing it in the top 42.2%.
Is Inotiv's 5-Year RORE % too high?
Inotiv's current 5-Year RORE % is -5.40. Based on the distribution chart, Inotiv ranks #76 out of 180 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint.
How does Inotiv's 5-Year RORE % compare to NSTM and PRPH?
According to the Medical Diagnostics & Research industry distribution chart, Inotiv ranks #76 out of 180 companies for 5-Year RORE %. This puts Inotiv in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year RORE % for a Medical Diagnostics & Research company?
A good 5-Year RORE % depends on the Medical Diagnostics & Research industry context. However, 5-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year RORE % mean?
A high 5-Year RORE % can signal that a stock is expensive relative to its fundamentals. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on Inotiv and its competitors. Inotiv's current 5-Year RORE % is -5.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inotiv stock overvalued right now?
Based on GuruFocus' analysis, Inotiv (STU:BS50) is currently considered Possible Value Trap. The stock's GF Value™ is €1.43, compared to a current price of €0.04 — trading 97.2% below its estimated fair value. The current 5-Year RORE % is -5.40. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year RORE % calculated?
5-Year RORE % is calculated from a company's financial statements. For Inotiv (STU:BS50), the current 5-Year RORE % is -5.40 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:BS50 has been successfully added to your 
